人血白蛋白序贯治疗对原发性肝癌合并肝硬化患者射频消融术后肝功能和预后的影响

肝脏 ›› 2021, Vol. 26 ›› Issue (5): 534-537.

人血白蛋白序贯治疗对原发性肝癌合并肝硬化患者射频消融术后肝功能和预后的影响

吉晓妹, 邵春燕, 吉浩明, 顾春燕

226600 南通大学附属海安医院肿瘤科(吉晓妹,邵春燕,吉浩明);
南通市第三人民医院肿瘤科(顾春燕)

收稿日期:2020-03-13 出版日期:2021-05-31 发布日期:2021-06-17
通讯作者: 吉晓妹,Email:1052893743@qq.com
基金资助:
南通市2018年度市级科技计划项目(JCZ18046)

Effect of sequential treatment of human albumin on liver function and prognosis in patients with primary liver cancer complicated with cirrhosis after radiofrequency ablation

JI Xiao-mei¹, SHAO Chun-yan¹, JI Hao-ming¹, GHAO Chun-yan²

1. Department of Oncology, Haian Hospital Affiliated to Nantong University, Jiangsu 226600,China;
2. Department of Oncology, the Third People's Hospital of Nantong, Jiangsu,226001,China

Received:2020-03-13 Online:2021-05-31 Published:2021-06-17
Contact: JI Xiao-mei, Email:1052893743@qq.com

摘要/Abstract

摘要： 目的探讨序贯应用人血白蛋白在原发性肝癌(PLC)合并肝硬化患者行超声引导下射频消融术(RFA)术后的疗效。方法选取110例行RFA的PLC合并肝硬化患者,观察组术后给予5%人血白蛋白和25%人血白蛋白序贯治疗,对照组给予5%人血白蛋白治疗,观察两组肝功能和疗效等数据。结果两组术后第1天和第3天ALB、γ-GT和TBil无差异(P>0.05),观察组第7天低于对照组(P<0.05);观察组第1天PAB和A/G低于对照组(P<0.05),第3天和第7天无差异(P>0.05)。观察组第1天和第3天GFR高于对照组(P<0.05);两组第7天无差异(P>0.05)。观察组第1天hs-CRP高于对照组(P<0.05),两组第3天时和第7天无差异(P>0.05)。两组术后PT和Fg均无差异(P>0.05)。观察组的白蛋白和血浆使用量及住院天数低于对照组(P<0.05);两组的并发症率和1年生存率无差异(P>0.05)。结论对行RFA的PLC合并肝硬化患者术后采用等渗和高渗人血白蛋白序贯治疗,能有效纠正低蛋白血症,补充血容量和维持内环境稳定,促进术后康复,提高白蛋白的利用效率。

关键词: 原发性肝癌, 肝硬化, 射频消融, 白蛋白, 序贯治疗

Abstract: Objective To investigate the effect of sequential treatment of human albumin (ALB) in patients with primary liver cancer (PLC) complicated with cirrhosis after ultrasound-guided radiofrequency ablation (RFA).Methods One hundred and ten PLC patients with cirrhosis treated with RFA were selected and divided into 2 groups. After RFA, the observation group was given 5% human ALB and 25% human ALB, while the control group was given 5% human ALB. Data such as liver function and treatment efficacy of the 2 groups were recorded.Results ALB, gamma-glutamyl transferase or total bilirubin had no significant difference between the 2 groups on the day 1 or day 3 after the operation (P>0.05), and they were lower in the observation group than control group on the day 7 (P<0.05). Prealbumin and ration of albumin and globulin were lower in the observation group than the control group (P<0.05) on the day 1 after the treatment, and had no significant difference on day 3 or day 7 (P>0.05). The glomerular filtration rate in the observation group was higher than the control group on day 1 and day 3 (P<0.05), and had no difference between the 2 groups on day 7 (P>0.05). High-sensitivity C-reactive protein was higher in the observation group than the control group on day 1 (P<0.05), and had no significant difference between the 2 groups on day 3 or day 7 (P>0.05). There was no significant difference in prothrombin time or fibrinogen between the 2 groups after treatment (P>0.05). The dosage of ALB and plasma and the time of hospitalization in the observation group were lower than those in the control group (P<0.05). There was no significant difference in complication rate or 1-year survival rate between the 2 groups (P>0.05).Conclusion The sequential treatment of isosmotic and hyperosmotic human ALB in PLC patients with cirrhosis after RFA can effectively improve hypoproteinemia and low blood volume, maintain internal environment stability, promote postoperative recovery and improve the utilization efficiency of ALB.

Key words: Primary liver cancer, Liver cirrhosis, Radiofrequency ablation, Albumin, Sequential treatment

吉晓妹, 邵春燕, 吉浩明, 顾春燕. 人血白蛋白序贯治疗对原发性肝癌合并肝硬化患者射频消融术后肝功能和预后的影响[J]. 肝脏, 2021, 26(5): 534-537.

JI Xiao-mei, SHAO Chun-yan, JI Hao-ming, GHAO Chun-yan. Effect of sequential treatment of human albumin on liver function and prognosis in patients with primary liver cancer complicated with cirrhosis after radiofrequency ablation[J]. Chinese Hepatolgy, 2021, 26(5): 534-537.

参考文献

[1] 邓照军,倪志,陈明霞.存在营养风险的原发性肝癌患者术前营养支持的效果及对免疫功能的影响.肝脏,2019,24:302-304.
[2] 李宏,高建龙,朱能,等.肝功能Child B级肝癌患者射频消融术后应用人血白蛋白的效果观察.山东医药,2016,56:66-68.
[3] 战旗,李悦悦,王晓俊,等.人血白蛋白在原发性肝癌肝切除术后的应用分析.山东医药,2015,33:463-466.
[4] 张汉洋,庄志彬,林春冬,等.经皮射频消融术与腹腔镜肝切除术治疗原发性小肝癌的疗效及预后比较.中国普通外科杂志,2019,28:24-30.
[5] Li QL,Li JD,Xu W,et al.Factors related to continual hypoproteinmia after hepatectomy for patients with hepatocellular carcinoma.Chin J Digest Surg,2012,11:151-154.
[6] 李健欣,韦德才,吴海波.人血白蛋白在肝硬化围手术期分配应用的疗效研究.中国现代普通外科进展,2017,20:577-579.
[7] 陈丽.人血白蛋白在肝硬化腹水患者中的系统评价.长沙:湖南师范大学,2014.
[8] 凌霞,田尧.CA125和白蛋白在肝硬化合并自发性细菌性腹膜炎诊断中的临床意义.肝脏,2016,21:946-948.
[9] Tunc S,Cetinkaya A,Duman O.Spectroscopic investigations of the interactions of tramadol hydrochlo-ride and 5-azacytidine hruga with human serum albumin and human hemoglobin proteins.J Photochem Photobiol B,2013,120:59-65.
[10] 吴金道,韩国勇,母小新,等.两种术后人血白蛋白治疗方案在肝癌合并肝硬化患者的应用效果.江苏医药,2015,41:3006-3008.
[11] 陈荣,王建春,周榆腾.三种不同人血白蛋白治疗方案在肝癌术后患者中的应用效果.中国医药导报,2015,36:71-74.
[12] 邓岩,王帅,喻晓,等.术前白蛋白/球蛋白比值在肝癌射频消融病人预后中的价值.腹部外科,2019,32:112-118.
[13] 曹青青,周瑾,李悦悦,等.高、低浓度人血白蛋白在原发性肝癌患者半肝切除术后的应用比较.实用临床医药杂志,2018,22:46-48.
[14] 丁俊,杨美平,张家耀.肝脏手术围术期应用等渗性和高渗性白蛋白的临床疗效比较.中国普外基础与临床杂志,2015,21:713-715.
[15] 赫嵘,蒋力,张珂,等.肝癌合并肝硬化患者术后人血白蛋白应用方案的临床研究.中华肝胆外科杂志,2014,20:11-14.
[16] 曾艳霞,袁群芳,程秋霞,等.营养支持对合并营养风险肝癌手术患者康复效果的影响.肝脏,2019,24:201-203.